Stock Ratings / Health Care / EDIT / financials

PROK (44) ALLO (38) AUTL (25) RGNX (39) ⌘ Pro Terminal →

Editas Medicine Inc. (EDIT) Revenue-to-Profit Sankey Flow & SEC XBRL Financials

$2.93 -0.68% NASDAQ • Live Quote vs Prior Daily Close (Synced Snapshot)

Editas Medicine Inc. (EDIT) carries a Roarable Rating of D- (Sell) with 37/100 RQD Confidence due to weak cash-flow efficiency and sensitivity to current interest rates. Wait for business cash flow and institutional buying to improve before committing fresh capital.

ROARABLE D- • RED ALERT Cap $450.0M

📤 Share Live RQD Speedometer Card: 𝕏 Post Reddit StockTwits ⬇ Live SVG Card

INTERACTIVE SCENARIO DECK:

🛡️ Portfolio Crash X-Ray

RQD QUANT TACHOMETERRED ALERT • D-

3-of-3 JEV AI Jury Bearish Warning

Cash

SEC

Whale

Impersonal quantitative research (0–100 RQD rubric) — not individualized investment advice. Past performance does not guarantee future results. Full Disclaimer

5-PILLAR SNOWFLAKE RADARRw E · Rk D

Each axis scored 0–20

12M PRICE TARGET CONE-9.6% Base Target

WHALE OPTIONS SNAPSHOT: — (No Active Options Snapshot on file for EDIT)Realized 20D OHLCV Swing Band: ±12.5%

VISUAL REVENUE-TO-PROFIT SANKEY WATERFALL • FY 2025 (10-K)

How EDIT Turns Every Dollar of Sales Into Real Bottom-Line Profit

Free Cash Flow:$0 (0% FCF Margin)

Multi-Year SEC EDGAR XBRL Revenue, Net Profit & Free Cash Flow Trajectory

■ Revenue■ Net Profit■ Free Cash Flow

FY23

Rev $78.1M

FY24

Rev $32.3M

FY25

Rev $40.5M

Fiscal Year	Revenue	Gross Margin	Op Margin	Net Profit	Free Cash Flow	ROIC %
FY 2025	$40.5M	52%	-80%	-$160.1M	-$165.8M	-45%
FY 2024	$32.3M	52%	-80%	-$237.1M	-$219.1M	-45%
FY 2023	$78.1M	52%	-80%	-$153.2M	-$132.2M	-35%

ON-DEMAND RQD QUANT WORKSHOP • SPONSORED / PARTNER SPOTLIGHTHosted by Perry Belcher & Roarable Forensic Quant Desk

Red-Light Warning Desk: Spotting SEC Cash-Flow & Dilution Risks Before Downgrades (Featuring EDIT)

✓Walkthrough of EDIT's RQD Radar, SEC cash-conversion gap & downside invalidation levels
✓3 asymmetric Bear/Hedge frameworks when 10-year Treasury yields stay elevated
✓Includes nightly RQD rating-change & forensic signal email alerts on your tracked stocks

RQD INSIDER CLUB WAITLIST$49/YR PLANNED

Want Custom AI PineScript / Python Indicators & Priority Rating-Change Alerts?

Join Founding VIP Waitlist (No Card Required) →$100K Arena

EDIT // CANDLESTICK & AUTO-TRENDLINE WORKSTATION6M: -2.33%▼ DESCENDING CHANNEL

2026-10-30O $2.89H $2.93L $2.60C $2.93VOL 2.91M

RES: $3.14SUP: $2.18SMA50: $2.76SMA200: $2.68

PRIMARY-SOURCE FORENSICS, SECOND-ORDER LINKS & AI ANALYST DESK

EDIT Dilution Monitor, Expectations Hurdle, Butterfly Connections & Policy Exposure

🦋 EDIT Butterfly Map → + Track EDIT →

Share Count & Dilution Monitor (#25)

Multi-year comparable XBRL diluted share count not disclosed (ETF or recent listing).

Reverse-DCF Expectations Hurdle (#30)

8.0%/yr Implied 5Y Growth

vs. +25.4% actual YoY revenue growth (assuming 9.25% cost of equity & 16.5x terminal multiple).

Ellis Vennor Setup Ledger (#33)

No active Ellis Vennor swing setup published on EDIT today. View full Setup Ledger →

🦋 Documented & Second-Order Butterfly Connections Open Graph →

No direct multi-tier Butterfly edges indexed yet for EDIT. Explore sector supply chains on /butterfly.

AI Analyst Theses, Washington Policy & Company Video

🎬 No recent verified company-specific video clip queued for EDIT today (we never pad ticker pages with unrelated generic clips). Browse Macro Video Desk →

DETERMINISTIC MULTI-FACTOR EQUITY AUDIT • SEC EDGAR XBRL × RQD PEER BENCHMARK

📊 Quantitative Sector Peer Comparison, SEC Filing Delta & Investment FAQ (EDIT)

Health Care Rank #747 of 1016 ⚔️ PROK vs EDIT Full Matrix →

1. Head-to-Head Health Care Peer Comparison (EDIT vs. PROK, ALLO, AUTL, RGNX)

Industry: Biotechnology: Biological Products (No Diagnostic Substances) (156 Tracked Issuers)

Across 1016 tracked Health Care securities in the Roarable RQD universe, Editas Medicine Inc. (EDIT) ranks #747 by composite RQD confidence (37/100, grade D-) and #466 by equity capitalization ($450.0M). Within this direct 5-issuer industry benchmark cohort, EDIT leads on earnings valuation at N/A trailing P/E, while EDIT leads on capital efficiency and profitability with -35.0% ROIC and — gross margin. PROK currently holds the highest overall quantitative score in the immediate peer group at 44/100 (D) compared with EDIT at 37/100 (D-).

Ticker / Company	Roarable Grade	RQD Score	Trailing P/E	Gross Margin	ROIC	1D Change	Market Cap	Head-to-Head
EDIT ACTIVE Editas Medicine Inc.	D-	37/100	—	—	-35.0%	-0.68%	$450.0M	Benchmark Subject
PROK ProKidney Corp. (Class A)	D	44/100	—	—	-35.0%	-3.29%	$444.4M	/prok-vs-edit →
ALLO Allogene Therapeutics Inc.	D-	38/100	—	—	-35.0%	-3.85%	$431.9M	/allo-vs-edit →
AUTL Autolus Therapeutics plc	E	25/100	—	-27.8%	-35.0%	-3.07%	$420.5M	/autl-vs-edit →
RGNX REGENXBIO Inc.	D-	39/100	—	—	-35.0%	+2.35%	$489.2M	/rgnx-vs-edit →

2. Multi-Year SEC XBRL Revenue, Cash Flow & Balance-Sheet Trajectory (FY2023–FY2025)

SEC EDGAR 10-K • FILED 2025-12-31 • CIK 0001650664

In its most recent audited fiscal period (FY2025, filed 2025-12-31), Editas Medicine Inc. (EDIT) reported GAAP revenue of $40.5M (+25.4% vs. FY2024 revenue of $32.3M , and -48.1% cumulative change since FY2023) , GAAP net income of -$160.1M, operating cash flow of -$165.2M, and free cash flow of -$165.8M (+24.3% YoY). On the balance sheet, EDIT closed FY2025 with $186.5M in total assets against $53.6M in total debt (Altman Z-Score: N/A, Piotroski F-Score: 3/9).

Fiscal Period	Filing Date	Revenue	Net Income	Operating Cash Flow	Free Cash Flow	Total Assets	Total Debt
FY2025 (FY)	2025-12-31	$40.5M	-$160.1M	-$165.2M	-$165.8M	$186.5M	$53.6M
FY2024 (FY)	2024-12-31	$32.3M	-$237.1M	-$210.3M	-$219.1M	$341.6M	$52.4M
FY2023 (FY)	2023-12-31	$78.1M	-$153.2M	-$132.2M	-$132.2M	—	—

3. EDIT Data-Verified Investor FAQ (RQD Rating, Sector Peers, SEC Forensics & Technicals)

✓ SCHEMA.ORG FAQPAGE JSON-LD ENABLED

Is EDIT stock a Buy, Hold, or Sell right now according to Roarable's RQD model?

As of 2026-11-01, Editas Medicine Inc. (NASDAQ: EDIT) is rated D- (Sell / SELL) by Roarable's 5-pillar RQD engine with a composite confidence score of 37/100 at a spot price of $2.93 (-0.68% 1D, market cap $450.0M). Pillar breakdown: Fundamental Cash Engine 6/20, Institutional 13F & Options Flow 9/20, Executive Insider Alignment 8/20, FRED Macro Regime Fit 11/20, and SEC Balance-Sheet Forensics 3/20. Across 1016 tracked Health Care issuers, EDIT ranks #747 in composite RQD confidence.

How does EDIT compare to PROK and ALLO in the Health Care sector?

Within the Health Care sector (Biotechnology: Biological Products (No Diagnostic Substances)), EDIT carries a Roarable D- (37/100 RQD), trailing P/E of N/A, gross margin of —, and ROIC of -35.0%. By comparison, PROK (ProKidney Corp. (Class A)) holds a D grade (44/100 RQD, P/E N/A, ROIC -35.0%, cap $444.4M) and ALLO (Allogene Therapeutics Inc.) posts a D- grade (38/100 RQD, P/E N/A, ROIC -35.0%, cap $431.9M). Among the 5-stock peer group, EDIT leads on earnings multiple (N/A) while EDIT leads on capital efficiency (-35.0% ROIC).

What are the biggest fundamental strengths and SEC risk factors for EDIT?

Per EDIT's SEC EDGAR XBRL 10-K filing (FY2025, filed 2025-12-31, CIK 0001650664), Editas Medicine Inc. generated $40.5M in revenue (+25.4% YoY), -$160.1M in net income, and -$165.8M in free cash flow against $186.5M in total assets and $53.6M in total debt. Key quantitative strengths: Established market leader in Health Care with deep daily trading liquidity.. Primary risk factors monitored: Company executives have done more routine share selling than personal cash buying lately.. Institutional options positioning shows a 50% call / 50% put premium split.

Where is EDIT trading relative to its 50-day, 200-day, and 52-week technical levels?

EDIT last traded at $2.93 (-0.68% on volume of 3,226,724 shares), positioning the stock +6.16% above its 50-day simple moving average ($2.76) and +9.33% above its 200-day simple moving average ($2.68). Across its 52-week range of $1.66 to $3.94, EDIT sits at the 55.7% percentile with a 14-day RSI of 50.8 (NEUTRAL RANGE) and an implied next-earnings move of ±12.5% ($2.56 to $3.30).

EDIT Investor FAQ & Complete 8-Part Research Index

100% OPEN ACCESS • SEC EDGAR × CBOE × FRED

How profitable is Editas Medicine Inc. (EDIT)?

In FY 2025 (10-K), EDIT converted $40.5M of revenue into a 52% gross margin, 0% operating margin, and $0 in free cash flow (0% FCF margin).

Direct Sub-Reports: EDIT RQD Cockpit EDIT 12M Forecast EDIT Earnings & Move EDIT Dividends & DRIP EDIT Insiders & 13F EDIT Whale Options EDIT Profit Sankey EDIT News & Why